That is a pity, there is no analysis of what happened with reporting results of phase 2b/3 study or Ananvex 2-73-AD-004. Just too much of twaddle. Why results were not recognized? I am new here and for me it is important to understand this. Maybe including the DNA analyses was absolutely new for analysts and FDA? Can anybody explain what happened?
Market Data 
Markets 
AI
